These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33832976)

  • 1. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
    Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
    Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
    Watson P; Brennan A; Birch H; Fang H; Petri M
    Rheumatology (Oxford); 2015 Apr; 54(4):623-32. PubMed ID: 25234659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study.
    Blazer A; Dey ID; Nwaukoni J; Reynolds M; Ankrah F; Algasas H; Ahmed T; Divers J
    Lupus Sci Med; 2021 Jan; 8(1):. PubMed ID: 33461980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
    Urowitz MB; Gladman DD; Ibañez D; Su J; Mursleen S; Sayani A; Ross Terres JA; Iczkovitz S
    J Rheumatol; 2021 Jan; 48(1):67-73. PubMed ID: 32238510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.
    Kandane-Rathnayake R; Kent JR; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra SA; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Hoi A; Nikpour M; Morand E
    Lupus; 2019 Dec; 28(14):1669-1677. PubMed ID: 31718467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.
    Becker-Merok A; Nossent HC
    J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
    Apostolopoulos D; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra S; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand E;
    Lancet Rheumatol; 2020 Jan; 2(1):e24-e30. PubMed ID: 38258272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
    Fessler BJ; Alarcón GS; McGwin G; Roseman J; Bastian HM; Friedman AW; Baethge BA; Vilá L; Reveille JD;
    Arthritis Rheum; 2005 May; 52(5):1473-80. PubMed ID: 15880829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort.
    Cann MP; Sage AM; McKinnon E; Lee SJ; Tunbridge D; Larkins NG; Murray KJ
    Lupus; 2022 Feb; 31(2):246-255. PubMed ID: 35037500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.
    Eudy AM; Siega-Riz AM; Engel SM; Franceschini N; Howard AG; Clowse MEB; Petri M
    Ann Rheum Dis; 2018 Jun; 77(6):855-860. PubMed ID: 29463519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort.
    Petri M; Purvey S; Fang H; Magder LS
    Arthritis Rheum; 2012 Dec; 64(12):4021-8. PubMed ID: 22932985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
    Joo YB; Bae SC
    Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.